Asciminib, an allosteric inhibitor specifically targeting the myristoyl pocket of BCR::ABL1, has expanded therapeutic options for heavily pretreated patients with chronic myeloid leukemia (CML), and for those with the BCR::ABL1 T315I mutation [1–3]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.